METABOLIC MECHANISMS OF TIRZEPATIDE IN ADIPOSE TISSUE REDUCTION AND AESTHETIC IMPLICATIONS
DOI:
https://doi.org/10.56238/revgeov17n3-215Keywords:
Adipocytes, Adipose Tissue, Energy Metabolism, Obesity, TirzepatideAbstract
The increasing prevalence of obesity and associated metabolic diseases represents a significant public health issue due to its clinical, metabolic, and aesthetic impacts. In this context, understanding the mechanisms involved in energy metabolism regulation and adipose tissue reduction becomes essential. Therefore, this study aimed to analyze the metabolic mechanisms of tirzepatide in reducing adipose tissue and its implications in the field of aesthetic biomedicine. This study is a qualitative literature review with a descriptive and exploratory approach, conducted through the analysis of scientific articles published in relevant health databases. Recent studies addressing the effects of tirzepatide on energy metabolism, adipose tissue, and metabolic outcomes were included. The results showed that tirzepatide acts through the activation of GIP and GLP-1 incretin receptors, promoting improved glycemic control, reduced food intake, and increased satiety. Additionally, the drug directly influences adipocyte metabolism by reducing lipid accumulation, modulating inflammatory processes, and enhancing fat utilization as an energy source. Improvements in insulin sensitivity and functional reorganization of adipose tissue were also observed. In conclusion, tirzepatide demonstrates high therapeutic potential in reducing adipose mass and regulating energy metabolism, with relevant impacts in both clinical and aesthetic contexts, standing out as a promising strategy for obesity treatment.
Downloads
References
BITTENCOURT, J. O. A. et al. Tirzepatide: Dual GIP/GLP-1 receptor agonists from molecular to clinical practice for treating type 2 diabetes and obesity. Indonesian Journal of Endocrinology and Metabolism, 2024. Disponível em: https://www.researchgate.net/publication/401688138_Tirzepatide_Dual_GIPGLP-1_Receptor_Agonists_from_Molecular_to_Clinical_Practice_for_Treating_Type-2_Diabetes_and_Obesity. Acesso em: 16 mar. 2026.
LI, Y. et al. Tirzepatide improves metabolic pathways in adipose and hepatic tissue. Frontiers in Endocrinology, 2025. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC12361993/. Acesso em: 16 mar. 2026.
LOOMBA, R. et al. Tirzepatide for metabolic dysfunction–associated steatohepatitis. The New England Journal of Medicine, 2024. Disponível em: https://www.natap.org/2024/EASL/NEJMoa2401943.pdf. Acesso em: 16 mar. 2026.
MESTRES-ARENAS, A. et al. Differential effects of the anti-obesity drug tirzepatide on adipose tissues. Biochemical Pharmacology, 2026. Disponível em: https://www.sciencedirect.com/science/article/pii/S0753332226000892. Acesso em: 16 mar. 2026.
PASE, M. A. et al. Tirzepatide: dual GIP/GLP-1 receptor agonists from molecular to clinical practice. Indonesian Journal of Endocrinology and Metabolism, 2024. Disponível em: https://www.researchgate.net/publication/401688138_Tirzepatide_Dual_GIPGLP-1_Receptor_Agonists_from_Molecular_to_Clinical_Practice_for_Treating_Type-2_Diabetes_and_Obesity. Acesso em: 16 mar. 2026.
REGMI, A. et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism. Cell Metabolism, 2024. Disponível em: https://www.cell.com/cell-metabolism/pdf/S1550-4131(24)00186-4.pdf. Acesso em: 16 mar. 2026.
SOKARY, S. et al. The promise of tirzepatide: a narrative review of metabolic outcomes. Diabetes & Metabolic Syndrome, 2025. Disponível em: https://www.sciencedirect.com/science/article/pii/S1751991825000816. Acesso em: 16 mar. 2026.
SUN, Y. et al. Tirzepatide reduces intracellular lipid accumulation in adipocytes. Biochemical Pharmacology, 2026. Disponível em: https://www.sciencedirect.com/science/article/pii/S0014299926000051. Acesso em: 16 mar. 2026.
XIA, Y. et al. Tirzepatide’s role in targeting adipose tissue macrophages and metabolic inflammation. Pharmacological Research, 2024. Disponível em: https://www.sciencedirect.com/science/article/pii/S1567576924020216. Acesso em: 16 mar. 2026.
ZHANG, A. et al. Tirzepatide reduces body weight by increasing fat utilization. Diabetes, Obesity and Metabolism, 2025. Disponível em: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16294. Acesso em: 16 mar. 2026.
